Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Transform Wealth LLC

Transform Wealth LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 97.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 291 shares of the biopharmaceutical company’s stock after selling 9,438 shares during the period. Transform Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $207,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Adirondack Trust Co. increased its holdings in Regeneron Pharmaceuticals by 2.4% in the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after buying an additional 10 shares during the last quarter. UMB Bank n.a. boosted its position in shares of Regeneron Pharmaceuticals by 1.1% during the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after acquiring an additional 10 shares in the last quarter. Trust Co. of Vermont increased its holdings in shares of Regeneron Pharmaceuticals by 8.3% in the 3rd quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock valued at $165,000 after acquiring an additional 12 shares during the last quarter. Nvwm LLC raised its position in shares of Regeneron Pharmaceuticals by 1.4% during the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock worth $1,039,000 after acquiring an additional 14 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 3.6% during the third quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock worth $456,000 after purchasing an additional 15 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 0.9 %

Shares of NASDAQ:REGN opened at $687.80 on Wednesday. The company has a market cap of $75.58 billion, a price-to-earnings ratio of 17.02, a PEG ratio of 1.61 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $666.25 and a fifty-two week high of $1,211.20. The firm’s 50-day simple moving average is $735.72 and its 200-day simple moving average is $946.39. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Sanford C. Bernstein dropped their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Bank of America reiterated an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, Royal Bank of Canada cut their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,015.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.